Neuland Laboratories Ltd
Neuland Laboratories Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Neuland expects a 20% growth rate in its pipeline based on the current projects (Page 18). Neuland expects a 20% growth rate in pipeline value, driven by attracting higher-value molecules and innovators (Page 18).
From Neuland Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Neuland expects a 20% growth rate in its pipeline based on the current projects (Page 18).
- The ramp-up of newly commercialized CMS molecules and expanded capacity, especially from Unit 3, is underway and anticipated to grow revenues over the next 2-3 years (Page 14).
- Growth in the next 2-3 years is "preordained" by existing products, requiring mainly execution (Page 14).
- Beyond 3-5 years, growth will be driven by investments in peptides and other novel modalities, geographic expansion, and cultivating large pharma partnerships (Pages 15-16).
- Long-term aspiration is a decadal growth of 20+% CAGR from 2026 to 2036, contingent on successful execution of strategic plans (Page 14).
2 more points from Neuland Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Neuland Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Neuland Laboratories has committed significant capital investment toward expanding peptide manufacturing capabilities, identifying a white space in large-scale peptide manufacturing driven by demand for new GLP-1 and amylin analogues.
- The company is building assets and focusing on monetizing these investments over the next 2-3 years to drive growth in the 3-5 year period.
- Board approved shifting the R&D facility to a new campus to build a state-of-the-art R&D center, enhancing innovation and scalability.
- Capex for 9MFY26 was INR 254 crores, in line with the company’s evolving business plan.
- Neuland is also exploring geographic expansion opportunities, potentially in the U.S. or Europe.
2 more points from Neuland Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Neuland Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The management emphasized a healthy pipeline of projects with a mix of commercial and development molecules.
- The company has about 19 commercial molecules in their portfolio, with 9 commercial APIs remaining steady.
- New molecule additions have occurred, with some older molecules removed, indicating active pipeline management.
- Ramp-up of capacity expansions and commercializations are ongoing, supporting future order fulfillment.
- The company focuses on quality projects and engaging with well-funded innovators and big pharma for sustained business development.
2 more points from Neuland Laboratories Ltd's call on order book
Create a free account to keep reading this call
Neuland Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neuland Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Neuland Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Neuland Laboratories Ltd Q3 FY26 results?
Neuland expects a 20% growth rate in its pipeline based on the current projects (Page 18). Neuland expects a 20% growth rate in pipeline value, driven by attracting higher-value molecules and innovators (Page 18).
What is Neuland Laboratories Ltd share price analysis?
Neuland Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 51.4 with a market cap of ₹25,603 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neuland Laboratories Ltd planning capital expenditure?
Neuland Laboratories has committed significant capital investment toward expanding peptide manufacturing capabilities, identifying a white space in large-scale peptide manufacturing driven by demand for new GLP-1 and amylin analogues. - The company is building assets and focusing on monetizing these investments over the next 2-3 years to drive growth in the 3-5 year period. - Board approved shifting the R&D facility to a new campus to build a state-of-the-art R&D center, enhancing innovation and scalability. - Capex for 9MFY26 was INR 254 crores, in line with the company’s evolving business plan. - Neuland is also exploring geographic expansion opportunities, potentially in the U.S.
Keep Neuland Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.